00000nam 2200000zi 4500 9.935753 CaOODSP 20241031101419 m o d f cr mn||||||||| 240321e20240517onc ob f000 0 eng d 9780660709390 (Statement) 9780660711027 (Summary) CaOODSP eng rda CaOODSP n-cn--- HP40-355/1-2024E-PDF HP40-355/2-2024E-PDF Statement on the prevention of respiratory syncytial virus (RSV) disease in infants. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, May 17, 2024. ©2024 1 online resource (68 pages) + summary (6 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. Issued also in French under title: Déclaration sur la prévention de la maladie causée par le virus respiratoire syncytial (VRS) chez les nourrissons. At head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Includes bibliographical references (pages 57-68). "Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by the age of 2 years old. RSV can cause serious respiratory disease in infants, young children and older adults. RSV has a seasonal pattern of activity where infections are usually more common in the winter with variation in the timing and magnitude of the peak. This statement focuses on the protection of infants and children from RSV disease"--page 6. Respiratory syncytial virus Vaccination Government policy Canada. Viral vaccines Government policy Canada. Vaccination of infants Government policy Canada. Vaccination of children Government policy Canada. Public Health Agency of Canada, issuing body. Déclaration sur la prévention de la maladie causée par le virus respiratoire syncytial (VRS) chez les nourrissons. (CaOODSP)9.935754 Statement on the prevention of respiratory syncytial virus (RSV) disease in infants. (CaOODSP)9.944716 PDF 993 KB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-355-1-2024-eng.pdf (Statement) PDF 351 KB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-355-2-2024-eng.pdf (Summary)